骨质疏松症的药物治疗新进展

被引:8
作者
曹丽梅
李波
机构
[1] 中国药品生物制品检定所国家药物安全评价中心
[2] 中国药品生物制品检定所国家药物安全评价中心 北京
[3] 北京
关键词
骨质疏松症; 降钙素; 骨形成促进剂; 骨吸收; 骨密度; 骨质密度; 药物治疗;
D O I
10.16153/j.1002-7777.2005.11.018
中图分类号
R58 [内分泌腺疾病及代谢病];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:42 / 45
页数:4
相关论文
共 23 条
[11]  
Favus,MJ,Christakos,S. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism . 1996
[12]  
Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. Silverberg SJ,Gartenberg F,Jacobs TP,et al. The Journal of Clinical Endocrinology . 1995
[13]  
Intravenous zoledronic acid in postmenopausal women with low bone density. IR Reid,JP Brown,P Burckhardt,Z Horowitz,P Richardson,U Trechsel,A Widmer,JP Devogelaer,JM Kaufman,P Jaeger,JJ Body,ML Brandi,J Broell,R Micco,AR Genazzani,D Felsenberg,J Happ,MJ Hooper,J Ittner,G Leb,H Mallmin,T Murray,S Ortolani,A Rubinacci,M Saaf,G Sam. The New England Journal of Medicine . 2002
[14]  
Skeletal effects of two years of treatment with low physiological doses of recombinant human growth horomone ( GH)in patients with aldult -onset GH deficiency. Janssen Y J,Handy N A,Frolich M,et al. The Journal of Clinical Endocrinology . 1998
[15]  
Growth hormone treatment of adults with growth hormone deficiency:results of a 13-month placebo controlled cross-over study. Whitehead HM,Boreham C,McIlrath EM,Sheridan B,Kennedy L,Atkinson AB,Hadden DR. Clinical Endocrinology . 1992
[16]  
Bone[P]. BIRL JOSEPH J.中国专利:US2436283A,1948-02-17
[17]  
Bone[P]. BIRL JOSEPH J.中国专利:US2436283A,1948-02-17
[18]  
Effect of fluoride treatment on the fracturerate in postmenopausal women with osteoporosis. RiggsBL,HodgsonSF,O‘FallonWM,ChaoEY,WahnerHW,MuhsJM,Cedel SL,Melton LJ, 3rd. The New England Journal of Medicine . 1990
[19]  
Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Kousteni S,Chen JR,BellidoT,et al. Science . 2002
[20]  
Circulating IGF-l: New Perspectives for a New Century. Rosen C J,Pollak M. Trends in Endocrinology and Metabolism . 1999